Product Information

CLINDA-TRETINOIN 1.2%-0.025% is a generic product labeled by Actavis Pharma, Inc., priced at $4.3282 per GM under NDC 00472179030. Its NADAC has been published 328 times since Oct 18, 2017.

FDA first approved this application on Jun 12, 2015. Its Orange Book therapeutic-equivalence code is AB1 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

CLINDA-TRETINOIN 1.2%-0.025%

Clindamycin Phosphate and Tretinoin
$4.3282per GM

Strength

12; .25 mg/g; mg/g

NDC

00472179030

Classification

Generic

Dosage Form

GEL

Route

TOPICAL

Effective Date

8/19/2026

Approval Type

Generic (ANDA)

FDA Application

ANDA202564

FDA Approved

6/12/2015

TE Code

AB1

On Market Since

7/5/2016

Pharmacological Classes

Decreased Sebaceous Gland Activity
Lincosamide Antibacterial
Lincosamides
Neuromuscular Blockade
Retinoid
Retinoids

Price Statistics

The NADAC for CLINDA-TRETINOIN 1.2%-0.025% has been published 328 times since Oct 18, 2017, and over the history we have for it it has declined 57.0%. The table below summarizes its recorded NADAC range and movement.

Current price$4.3282 per GM
All-time high$10.0889 (Oct 16, 2019)
All-time low$4.3282 (Aug 19, 2026)
52-week high$4.9717
52-week low$4.3282
Median price$6.2350
Average price$7.0823
Largest weekly change-40.9% (May 18, 2022)
Weeks tracked328
Tracking sinceOct 18, 2017

Price History

1W

-6.0%

1M

-6.0%

3M

-12.9%

6M

-5.4%

1Y

-4.5%

3Y

-42.8%

5Y

-57.1%

All

-57.0%

Generic Alternatives

The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 22% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Lowest-Cost Alternatives

Save up to 22%

1 alternative • Same active ingredient

Frequently asked questions

What is the NADAC price of CLINDA-TRETINOIN 1.2%-0.025%?

The current National Average Drug Acquisition Cost (NADAC) for CLINDA-TRETINOIN 1.2%-0.025%, manufactured by Actavis Pharma, Inc., is $4.3282 per GM (NDC 00472179030), effective Aug 19, 2026.

How has the price of CLINDA-TRETINOIN 1.2%-0.025% changed over time?

Over the history we have for it, the NADAC for CLINDA-TRETINOIN 1.2%-0.025% has declined 57.0%. It has been tracked across 328 weekly CMS publications since Oct 18, 2017.

What are the highest and lowest recorded NADAC prices for CLINDA-TRETINOIN 1.2%-0.025%?

Since Oct 18, 2017, the NADAC for CLINDA-TRETINOIN 1.2%-0.025% has ranged from a low of $4.3282 (Aug 19, 2026) to a high of $10.0889 (Oct 16, 2019), with a median of $6.2350 per GM.

Are there cheaper alternatives to CLINDA-TRETINOIN 1.2%-0.025%?

Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, CLINDA-TRETINOIN 1.2%-0.025%, is $3.3975 per GM — about 22% below CLINDA-TRETINOIN 1.2%-0.025%.

Who manufactures CLINDA-TRETINOIN 1.2%-0.025%?

CLINDA-TRETINOIN 1.2%-0.025% (NDC 00472179030) is labeled by Actavis Pharma, Inc., and CMS classifies it as a generic product.